Drug intelligence / Profile preview

Live-attenuated Streptococcus pneumoniae vaccine

Development stage: Preclinical
Lead developer: Onconetix
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal, Intraperitoneal, Intracerebroventricular

Overview

A live-attenuated vaccine designed to provide broader, serotype-independent protection against pneumococcal infections. This vaccine aims to address the limitations of existing capsule-targeted vaccines and combat diseases caused by *Streptococcus pneumoniae*, including pneumonia, acute otitis media, acute sinusitis, and invasive diseases, which are a leading cause of pediatric death. Blue Water Vaccines licensed the patent rights for global development from St. Jude Children's Research Hospital.

Other names: streptococcus pneumoniae live-attenuated vaccineUniversal Live Attenuated Streptococcus Pneumonia Bacteria Vaccinelive-attenuated Streptococcus pneumoniae vaccine

Beyond the preview

Go deeper on Live-attenuated Streptococcus pneumoniae vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Live-attenuated Streptococcus pneumoniae vaccine.